Ser1157

Site Information
SAKSsEMsPVPMRSA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23137441

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 )
Disease tissue studied:	breast cancer ( 5 , 11 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 5 ) , leukemia ( 13 ) , acute myelogenous leukemia ( 13 ) , lung cancer ( 7 , 11 ) , non-small cell lung cancer ( 11 ) , non-small cell lung adenocarcinoma ( 7 ) , pancreatic ductal adenocarcinoma ( 6 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 6 ) , A549 (pulmonary) ( 8 ) , breast ( 1 , 5 ) , BT-20 (breast cell) ( 11 ) , BT-549 (breast cell) ( 11 ) , H2077 (pulmonary) ( 11 ) , H322M (pulmonary) ( 11 ) , HCC366 (pulmonary) ( 11 ) , HCC78 (pulmonary) ( 11 ) , HeLa (cervical) ( 4 , 10 , 14 ) , HOP62 (pulmonary) ( 11 ) , Jurkat (T lymphocyte) ( 9 , 15 ) , K562 (erythroid) ( 10 ) , KG-1 (myeloid) ( 13 ) , lung ( 7 ) , MDA-MB-231 (breast cell) ( 11 ) , MDA-MB-468 (breast cell) ( 11 ) , NCI-H157 (pulmonary) ( 11 ) , NCI-H1666 (pulmonary) ( 11 ) , NCI-H322 (pulmonary) ( 11 ) , NCI-H520 (squamous) ( 11 ) , PC9 (pulmonary) ( 11 ) , WM239A (melanocyte) ( 3 )

Upstream Regulation
Treatments:	ischemia ( 5 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
3	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
4	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
5	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
6	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
7	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
8	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
9	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
10	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
11	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
12	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
13	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
14	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
15	Possemato A (2010) CST Curation Set: 9619; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info